Assessment of quality of life in women undergoing hormonal therapy for breast cancer: Validation of an endocrine symptom subscale for the FACT-B

Breast Cancer Research and Treatment

Volumn 55, Issue 2, 1999, Pages 189-199

  Fallowfield, Lesley J ^a   Leaity, Samantha K ^a   Howell, Anthony ^b   Benson, Sarah ^b   Cella, David ^c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Breast cancer; Endocrine therapy; FACT B; FACT ES; Quality of life

Indexed keywords

ANASTROZOLE; MEGESTROL; TAMOXIFEN;

ADULT; AFFECTIVE NEUROSIS; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; DIARRHEA; FEMALE; HEADACHE; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; IRRITABILITY; MAJOR CLINICAL STUDY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; RATING SCALE; SIDE EFFECT; SOCIAL INTERACTION; TREATMENT OUTCOME; VAGINA BLEEDING; VAGINA DISCHARGE; VAGINA DISEASE; VERTIGO; VOMITING; WEIGHT GAIN; WELLBEING;

EID: 0032796707     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/a:1006263818115     Document Type: Article

References (16)

1. Brady MJ, Cella DF, Mo F, et al.: Reliability and validity of the Functional Assessment of Cancer Therapy-Breast (FACT-B) quality of life instrument. J Clin Oncol 15: 974-986, 1997
2. Howell A, Downey S, Anderson E: New endocrine therapies for breast cancer. Eur J Cancer 32A(4): 576-588, 1996
3. Jonat W, Howell A, Blomqvist C, et al.: A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer 32A(3): 404-412, 1996
4. Couzi RJ, Helzlsouer K, Fetting JH: Prevalence of menopausal symptoms among women with a history of breast cancer and attitudes toward estrogen replacement therapy. J Clin Oncol 13: 2737-2744, 1995
5. Love RR, Cameron L, Connell BL: Symptoms associated with tamoxifen treatment in postmenopausal women. Archives Int Med 151: 1842-1847, 1991
6. Kornblith AB, Hollis DR, Zuckerman E: Effect of megestrol acetate on quality of life in a dose-response trial in women with advanced breast cancer, J Clin Oncol II: 2081-2089, 1993
7. Hayes DF, Van Zyl JA, Hacking A: Randomized comparison of tamoxifen with two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J Clin Oncol 13: 2556-2566, 1995
8. Leonard RCF, Lee L, Harrison ME: Impact of side effects associated with endocrine treatments for advanced breast cancer: Clinicians' and patients' perceptions. The Breast 5: 259-264, 1996
9. Hopwood P: Living with advanced breast cancer: Development and application of a clinical checklist for patients on endocrine therapy. The Breast 7: 14-21, 1998
10. Daly E, Gray A, Barlow D, McPherson K, Roche M, Vessey M: Measuring the impact of menopausal symptoms on quality of life. Br Med J 307: 836-840, 1993
11. Canney PA, Hatton MQF: The prevalence of menopausal symptoms in patients treated for breast cancer. Clin Oncol 6: 297-299, 1994
12. Cella D: Manual for the Functional Assessment of Cancer Therapy (FACT) quality of life instrument (Version 4). Evanston Northwestern Healthcare, Evanston, II, USA, 1997
13. Streiner DL, Norman GR: Health Measurement Scales. Oxford University Press, New York, 1989
14. Nunnally JC: Psychometric Theory, 2nd Edition. McGraw-Hill, New York, 1978
15. Cella DF, Bonomi AE, Lloyd SR, Tulskey DS, Kaplan E, Bonomi P: Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer 12: 199-220, 1995
16. Bonomi AE, Cella DF, Hahn EA, et al.: Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Qual Life Res 5: 309-320, 1996